Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELQ-453
- Development stage
- Preclinical
- Lead developer
- Harvard University
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
ELQ-453 is an endochin-like quinolone (ELQ) prodrug that acts as a potent inhibitor of the ubiquinol oxidation (Qo) site of the cytochrome bc1 complex (CytB) in the mitochondrial electron transport chain of *Plasmodium falciparum*. It is enzymatically converted by host esterases to its active form, ELQ-121. Developed by researchers at Harvard University and Oregon Health & Science University, ELQ-453 is designed for mosquito-targeted antimalarial interventions. When incorporated into bed net-like low-density polyethylene (LDPE) films, ELQ-453 is absorbed through the mosquito's legs (tarsal contact) and completely blocks *P. falciparum* infection and transmission without killing the mosquito vector, thereby avoiding the selection of insecticide resistance.
02
Targets
bc1 complex (Cytochrome bc1 complex (plasmodium))
Beyond the preview
Go deeper on ELQ-453.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELQ-453.